IMV Commences Trading on the TSX and Nasdaq Post 1:10 Reverse Stock Split

Author: Charles Gross | December 13, 2022 07:06am
IMV Inc. (the "Corporation" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today. As announced and previously approved by shareholders on December 7, 2022, the Corporation has consolidated its outstanding common shares on the basis of one new common share for every 10 outstanding common shares. The consolidation has taken effect on December 7, 2022, and the Corporation's common shares commence trading on the Toronto Stock Exchange and on the Nasdaq Capital Market ("Nasdaq") under the name IMV Inc. on a post-consolidation basis at the opening of markets today. The consolidation is primarily intended to bring the Corporation into compliance with the minimum required closing bid price for continued listing on Nasdaq of US$1.00 per share.

Posted In: IMV TSX:IMV